Lara Sullivan
Chief Executive Officer at PYXIS ONCOLOGY, INC.
Net worth: 8 M $ as of 2024-03-30
Profile
Lara S.
Sullivan is the founder of SpringWorks Therapeutics LLC, which was founded in 2017.
She held the title of President & Director during her time there from 2017 to 2018.
Currently, Dr. Sullivan is the President, Chief Executive Officer & Director at Pyxis Oncology, Inc., starting in 2019.
In her former positions, she was a Director at Rexahn Pharmaceuticals, Inc. She also served as Vice President at Pfizer Inc. from 2011 to 2017.
Prior to that, she worked as an Associate at McKinsey & Co., Inc. In terms of education, Dr. Sullivan completed her undergraduate studies at Cornell University.
She then obtained an MBA from The Wharton School of the University of Pennsylvania.
She also holds a graduate degree from the Perelman School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PYXIS ONCOLOGY, INC.
3.21% | 2024-03-25 | 1,866,547 ( 3.21% ) | 8 M $ | 2024-03-30 |
Lara Sullivan active positions
| Companies | Position | Start |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Chief Executive Officer | 2019-12-10 |
Former positions of Lara Sullivan
| Companies | Position | End |
|---|---|---|
SpringWorks Therapeutics LLC
 SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | Founder | 2017-12-31 |
| PFIZER, INC. | Corporate Officer/Principal | 2016-12-31 |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
| REXAHN PHARMACEUTICALS, INC. | Director/Board Member | - |
Training of Lara Sullivan
| Cornell University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Perelman School of Medicine | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| PYXIS ONCOLOGY, INC. | Health Technology |
| Private companies | 3 |
|---|---|
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | Health Technology |
- Stock Market
- Insiders
- Lara Sullivan
